Evogene Ltd (EVGN)

Nasdaq: EVGN · Agricultural Chemicals · Rehovot, IL · filing with the SEC since 2013

Full chart Alerts Compare

Grade4.0

◀ Past 3.5● Present 4.2▶ Future 4.4

2 est.

Overview Business Financials Grade Forecast Sentiment Ownership People Filings Patents Chart

The grade of Evogene Ltd

Nine metrics read from its own filings, by tense

Headline grade

4.0/10

◀ Past3.530% of the headline

● Present4.240% of the headline

▶ Future4.430% of the headline

All three tenses have at least two readings, so the archetype blend applies as printed.

Of the nine metrics, 7 read as filed from the record and 2 are SI estimates, each with its reasoning, its confidence and what would change it on its card.

◀ Past

What did they actually do?

3.5/1030% of the headline grade · 2 of 3 filed, 1 estimated

Surviving crises

as filed

7.5/10

Has it survived what it has been through?

No warning events in its filings since 2017.

weight 33% of this tense · 75th percentile among 12 sector filers · read for itself

From the record

Evogene Ltd's filings since 2017 show no warning events in the scan: no bankruptcy or receivership notice, no debt default notice, no exchange listing notice, no restatement warning, no auditor change, no material cyber incident and no late-report notice (its current reports).

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Track record

as filed

1.1/10

What has it actually done, year after year?

-5.7% a year over 10 filed years; profitable in 0 of 10.

weight 45% of this tense · 11th percentile among 11 sector filers · read for its customers

From the record

Evogene Ltd's 10 filed years say what it did: revenue went from $7 million in fiscal 2016 to $4 million in fiscal 2025, down 5.7% a year; it rose in 4 of 9 years; the deepest fall was 88% from fiscal 2016 to fiscal 2019; net income was positive in 0 of 10 of those years (its annual reports).

What it rests on

revenue growth over the filed span-5.7%bottom 5% of its family
the share of years revenue rosebottom 14% of its family
the share of filed years with a profitbottom 14% of its family
the deepest fall from a revenue peak88.5%bottom 14% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Shareholder treatment

SI estimate

2.3/10

How has it treated the people who own it?

SI estimate 2.3/10, confidence 35 of 100 (one part).

weight 22% of this tense · 23rd percentile among 11 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate: Read from one part only, the share count over the years, which ranks in the bottom 23% of 11 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
What the record cannot read: Fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
How it was reasoned: one part: the share count over the years, the one part on file, ranked among 11 in its family.
Confidence: 35 of 100
What would change it: A filing that carries the missing parts replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Evogene Ltd's shareholder treatment is put at 2.3 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the bottom 23% of 11 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.

● Present

What are they doing right now?

4.2/1040% of the headline grade · 2 of 3 filed, 1 estimated

Financial health

as filed

3.6/10

Is it financially healthy right now?

ROE -65%: lost 65¢ per shareholder dollar. Leverage 40%: owes 40¢ per asset dollar.

weight 45% of this tense · 36th percentile among 10 sector filers · read for itself

From the record

Return on equity: in the fiscal year ended 2025-12-31, Evogene Ltd lost about 65 cents for every dollar of shareholders' money, and gross profitability: its products earned less than nothing, about minus 1 cents per dollar of everything the company owns. Leverage: it owed about 40 cents per dollar of assets, and net share issuance: its share count grew 38.2% over the year (the filed statements).

What it rests on

what it owes per dollar of assetstop 15% of its family
return on equitybottom 28% of its family
gross profit against assetsbottom 6% of its family
the share count against the year beforebottom 25% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Industry position

as filed

4.4/10

How strong is its position in its industry?

bottom 44% of 11 in its family; net margin -203.1%.

weight 33% of this tense · 44th percentile among 11 sector filers · read for its customers

From the record

Evogene Ltd's standing among 11 graded names in its industry family: revenue of $4 million in fiscal 2025 ranks in the bottom 23% by size; a net margin of -203.1% ranks in the bottom 23%; revenue growth of 32% a year over the last 3 filed years ranks in the top 14% (its annual reports).

What it rests on

revenue against the family$3.9Mbottom 23% of its family
net margin-203.1%bottom 23% of its family
three-year revenue growth32.0%top 14% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Leadership

SI estimate

5.0/10

What are the people in charge doing?

SI estimate 5.0/10, confidence 20 of 100 (family median).

weight 22% of this tense · 50th percentile among 7 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate: It files no Form 8-K (a foreign issuer reports on Form 6-K), so officer and director changes cannot be read there; the record of its people begins on 2026-03-18 (a listing, a merger or a first filing under the rules) and its chief executive and most of the people in charge have filed since then, so the record shows a floor of 8 months and cannot see past it; a floor under five years is not read as years in charge, so the desk assumes the typical reading of its industry family, the median of 7 members with one.
What the record cannot read: It files no Form 8-K (a foreign issuer reports on Form 6-K), so officer and director changes cannot be read there; the record of its people begins on 2026-03-18 (a listing, a merger or a first filing under the rules) and its chief executive and most of the people in charge have filed since then, so the record shows a floor of 8 months and cannot see past it; a floor under five years is not read as years in charge.
How it was reasoned: family median, 7 readings behind it.
Confidence: 20 of 100
What would change it: Its next annual report on file with the inputs replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Evogene Ltd's leadership is put at 5.0 of 10 with a confidence of 20 of 100, because it files no Form 8-K (a foreign issuer reports on Form 6-K), so officer and director changes cannot be read there; the record of its people begins on 2026-03-18 (a listing, a merger or a first filing under the rules) and its chief executive and most of the people in charge have filed since then, so the record shows a floor of 8 months and cannot see past it; a floor under five years is not read as years in charge, so the desk assumes the typical reading of its industry family, the median of 7 members with one. Its next annual report on file with the inputs replaces this estimate with the filed reading.

▶ Future

What are they set up to do next?

4.4/1030% of the headline grade · 3 of 3 filed

Room to expand

as filed

4.8/10

How much room does it have to grow?

bottom 48% of 11 in its family for room to expand.

weight 45% of this tense · 48th percentile among 11 sector filers · read for itself

From the record

Evogene Ltd's room to grow, from the newest filed statements (fiscal 2025): cash of $13 million against no long-term debt tagged leaves 64.6% of its assets as net cash, top 5% of its family; cash from operations less capital spending is -353.9% of revenue (bottom 14%); a gross margin of -6.3% (bottom 5%); research spending of 207.5% of revenue (top 21%) (its annual report).

What it rests on

cash less debt against assets64.6%top 5% of its family
cash from operations less capital spending against revenue-353.9%bottom 14% of its family
gross margin-6.3%bottom 5% of its family
research spending against revenue207.5%top 21% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Growth drivers

as filed

2.6/10

What could actually drive growth from here?

bottom 26% of 11 in its family for growth drivers.

weight 33% of this tense · 26th percentile among 11 sector filers · read for its customers

From the record

Evogene Ltd's growth drivers, from the filed years to fiscal 2025: revenue grew 32% a year over the last three filed years against -5.7% over all 10, speeding up (top 14% of its family); the newest year grew -30.9% (bottom 5%); research spending grew -27.3% a year (bottom 7%); capital spending grew -51.3% a year (bottom 6%) (its annual reports). Evogene Ltd tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.

What it rests on

three-year growth against the whole span+37.7 points a yeartop 14% of its family
the newest year's revenue growth-30.9%bottom 5% of its family
three-year growth of research spending-27.3%bottom 7% of its family
three-year growth of capital spending-51.3%bottom 6% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Expectations vs reality

as filed

6.2/10

Did its newest year beat what its own record pointed to?

top 38% of 11 in its family for expectations against reality.

weight 22% of this tense · 62nd percentile among 11 sector filers · read for its shareholders

From the record

Evogene Ltd's newest year against its own record: revenue of $4 million in fiscal 2025 came in 62.1% below the $10 million its prior three years' pace pointed to (bottom 14% of its family); net income of $8 million against a prior three-year average of $25 million (top 14%); a net margin of a loss larger than its revenue against losses larger than its revenue before (top 14%) (its annual reports).

What it rests on

revenue against the prior three years' pace-62.1%bottom 14% of its family
net income against the prior three years' average+68%top 14% of its family
net margin against its prior averageup more than 100 pointstop 14% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made

SI Assistanton EVGN · research, not advice